Last reviewed · How we verify
Biological: Etanercept and its biosimilars
Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine driving immune-mediated diseases.
Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine driving immune-mediated diseases. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.
At a glance
| Generic name | Biological: Etanercept and its biosimilars |
|---|---|
| Also known as | Enbrel, Eucept, Etalace |
| Sponsor | Hanyang University Seoul Hospital |
| Drug class | TNF receptor antagonist / TNF inhibitor |
| Target | TNF-α and TNF-β |
| Modality | Biologic |
| Therapeutic area | Immunology / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Etanercept consists of the extracellular ligand-binding domain of the human TNF receptor p75 fused to the Fc portion of human IgG1. It acts as a soluble TNF receptor that competitively binds circulating TNF-α and TNF-β, preventing their interaction with cell-surface TNF receptors and thereby suppressing the inflammatory cascade. This mechanism reduces pathogenic immune activation in autoimmune and inflammatory conditions.
Approved indications
- Rheumatoid arthritis
- Ankylosing spondylitis
- Psoriatic arthritis
- Polyarticular juvenile idiopathic arthritis
- Plaque psoriasis
- Crohn's disease
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Serious infections (including tuberculosis)
- Demyelinating disease
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |